Recorlev was Xeris Biopharma Holdings’s largest product and service line in fiscal 2025, bringing in $139.28M of $291.85M (48%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Gvoke | $52.53M | $67.05M | $82.83M | $94.11M | |
| Recorlev | $7.43M | $29.55M | $64.28M | $139.28M | |
| Keveyis | $49.31M | $56.77M | $49.53M | $47.65M | |
| Royalty, Contract & Other Revenue | $985.00K | $10.55M | $6.43M | $8.84M | |
| Other Product Revenue | — | — | — | $1.96M | |
| Total | $110.25M | $163.91M | $203.07M | $291.85M |
Xeris Biopharma Holdings brought in $291.85M from its five product and service lines in fiscal 2025, the year ended December 31, 2025. Xeris Biopharma Holdings regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $203.07M. Recorlev was the largest at $139.28M (47.7%), ahead of Gvoke at $94.11M (32.2%) and Keveyis at $47.65M (16.3%). The other two lines brought in $10.81M combined.
Compared with fiscal 2024, Recorlev grew fastest, up 116.7% to $139.28M, while Keveyis fell the most, down 3.8% to $47.65M.
Xeris Biopharma Holdings began breaking out Other Product Revenue in fiscal 2025, when it brought in $1.96M.
Xeris Biopharma Holdings (XERS) reports its revenue by product and service. In fiscal 2025, Recorlev was its largest product and service line, bringing in $139.28M (47.7% of the total), followed by Gvoke at $94.11M (32.2%).
Recorlev was Xeris Biopharma Holdings' largest product and service line in fiscal 2025, bringing in $139.28M, or 47.7% of the $291.85M total across its five product and service lines.
Every figure comes from Xeris Biopharma Holdings' annual financial filings, as reported. Each line keeps the name Xeris Biopharma Holdings gives it, and years follow its fiscal calendar.
Xeris Biopharma Holdings' revenue by product and service goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.